PHOSLO Drug Patent Profile
✉ Email this page to a colleague
When do Phoslo patents expire, and when can generic versions of Phoslo launch?
Phoslo is a drug marketed by Fresenius Medcl and is included in two NDAs.
The generic ingredient in PHOSLO is calcium acetate. There are two hundred and eighty-two drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phoslo
A generic version of PHOSLO was approved as calcium acetate by HIKMA on February 26th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PHOSLO?
- What are the global sales for PHOSLO?
- What is Average Wholesale Price for PHOSLO?
Summary for PHOSLO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Clinical Trials: | 7 |
| Drug Prices: | Drug price information for PHOSLO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PHOSLO |
| What excipients (inactive ingredients) are in PHOSLO? | PHOSLO excipients list |
| DailyMed Link: | PHOSLO at DailyMed |
Recent Clinical Trials for PHOSLO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Azienda Ospedaliera Sant'Anna | N/A |
| Amgen | N/A |
| Albany College of Pharmacy and Health Sciences | Phase 4 |
US Patents and Regulatory Information for PHOSLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PHOSLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PHOSLO
See the table below for patents covering PHOSLO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1333884 | FIXATEUR DE PHOSPHORE (PHOSPHOROUS BINDER) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PHOSLO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 122018000145 | Germany | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 2957286 | C02957286/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66411 22.12.2017 |
| 2957286 | LUC00094 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2957286 | CR 2018 00043 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| 0521471 | SPC/GB03/033 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321 |
| 0933372 | PA2008006 | Lithuania | ⤷ Sign Up | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
